Bourgoin, France

Our Bourgoin facility, a Center of Excellence for late-stage development and commercialization of oral solid dose (OSD) products, is now offering early development capabilities to complete the end-to-end journey for your molecule.

Bourgoin provides fast, flexible small-scale work combined with robust full-scale processes. Bourgoin is our leading EU site for commercialization of OSD products, specializing in high-potency drugs and small-scale manufacturing for niche indications. The site’s multimillion-euro investment in early development capabilities brings state-of-the-art equipment and expertise to the region.

Specialized Capabilities

Areas of expertise include:

• Handling highly potent APIs up to Cat 3b, including cytostatic
• Successful transfer and commercialization of development projects for EU, US, and Japanese markets
• High-potency products
• FDA approved, including product development services
• Orphan/niche indication products
• Non-sexual hormones

Bourgoin’s capabilities include solid dose early development, manufacturing, packaging, and highly potent handling of:

• Tablets
• Capsules
• Powders and granules
• High-potency products

This site features a strong regulatory inspection history from all major international regulatory agencies. Additionally, we are making continued investments in the site both in capital and scientific resources.

Learn more about the specific equipment and capabilities at this site by downloading our Site Fact Sheet.